Research by a Pittsburgh physician could help women diagnosed with ovarian cancer determine the most effective chemotherapy treatments with their doctors.

The study, led by Dr. Thomas Krivak, assistant director of Gynecological Oncology at West Penn Allegheny Health Systems, supports the ChemoFx chemoresponse assay, a tool used to accurately predict how individual women will respond to platinum-based chemotherapy for ovarian cancer.